A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analía Azaro, Christophe Massard, William D. Tap, Philippe A. Cassier, Jaime R. Merchan, Antoîne Italiano, Bailey Anderson, Eunice Yuen, Danni Yu, Gerard J. Oakley, Karim A. Benhadji, Shubham Pant
Topics & Concepts
Notch signaling pathwayMedicineSolid tumorCancer researchPharmacologyCancerInternal medicineReceptorAdvanced Breast Cancer TherapiesNeuroendocrine Tumor Research AdvancesCancer Mechanisms and Therapy